|
|
||||||||
Ann Thorac Surg 2000;70:1720-1721
© 2000 The Society of Thoracic Surgeons
a Service de Chirurgie Thoracique et Vasculaire, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France
Address reprint requests to Dr Regnard, Service de Chirurgie Thoracique et Vasculaire, Centre Chirurgical Marie Lannelongue, 133 Av de la Resistance, 92350 Le Plessis Robinson, France
e-mail: jean-francois.regnard{at}htd.ap-hop-paris.fr
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
A 49-year-old white man, current heavy smoker, presented for mild right chest pain and body weight loss. Chest x-ray film revealed a right-sided paratracheal opacity. Fiberoptic bronchoscopy showed no abnormalities. Thoracic computed tomographic (CT) scan confirmed the presence of a solid mass in the right upper lobe in close contact with the right brachiocephalic vein and superior vena cava (SVC). There were no enlarged mediastinal lymph nodes. Brain CT scan, bone scintigraphy, and abdominal ultrasonography revealed no distant metastases. Thoracic magnetic resonance imaging (MRI) (Fig 1) and phlebocavography suggested tumoral invasion of the right brachiocephalic vein as well as the origin of SVC.
|
Postoperative course was initially favorable. On the 10th postoperative day, fever and a mild dyspnoea appeared. Chest x-ray film was consistent with right pneumonia. Fiberoptic bronchoscopy showed a healing right upper bronchial stump. Laboratory examinations showed leukocytosis. Cultures of bronchial aspirate and blood were sterile. An antibiotic treatment was started (AmoxicillinClavulanate [SmithKline Beecham, Philadelphia, PA] and, subsequently, in the absence of clinical improvement, Sparfloxacin [Bristol-Myers Squibb, Princeton, NJ] and Ornidazol [Roche, Basel, Switzerland]). Patients conditions and chest x-ray results improved allowing the discharge on the 21st postoperative day. Despite continuing antibiotherapy, 3 days later, a new hospitalization was necessary for the worsening of clinical conditions. Thoracic CT scan revealed a destroyed right lung parenchyma with a pleural effusion and an hydroaeric level.
A reoperation was decided in this obvious empyema. At thoracotomy the lung parenchyma was almost entirely condensed; a localized empyema occupied the superior part of the hemithorax, the prosthesis soaked in the pus. The cavity was carefully debrided and washed with antiseptic solution. A completion pneumonectomy was necessary in the presence of a destroyed lung. A latissimus dorsi flap was mobilized, passed through the third intercostal space, and used to cover both the stump of main bronchus and the prosthesis, as well as to partially fill the cavity.
Postoperative course was uneventful, apyrexia was observed on the 2nd postoperative day. Cultures of specimens of empyema grew E coli and E faecalis. Based on in vitro sensitivity tests, ImipenemCilastatin [Merck, Sharp & Dohme, Whitehouse Station, NJ] and Amikacin [Rhone-Poulenc Rorer, Paris, France] were administered for 14 days. No pleural space irrigation was performed. A chest tube was maintained in the immediate postoperative course, and repeat gram stains from the pleural fluid were performed daily. As all these gram stains were negative, the chest tube was removed on day 5. On the 15th postoperative day, the patient was discharged home. No recurrence of infection occurred. Regular follow-up revealed no relapse of lung cancer, and patency of prosthesis 4 years later.
| Comment |
|---|
|
|
|---|
In our patient, both phlebography and MRI had suggested tumoral invasion of both SVC and right innominate vein. So the resection was performed through a median sternotomy due to the difficulty to correctly control the innominate vein through a thoracotomy. Venous pathway was reestablished by a graft interposition between the left innominate vein and the SVC stump. In fact, when the origin of the SVC is invaded, the revascularization of a single innominate vein is recommended; it is sufficient and provides a higher flow through the prosthesis than if both innominate veins are revascularized [4].
Infection represents a major complication of lung resection with SVC replacement [4]. When mediastinitis or empyema occur, the risk of a life-threatening graft infection is obviously enormous [4]. Due to the exiguity of published series, no consensus exists concerning the optimal management of this complication. Open window thoracostomy combined with progressive clamping of the graft and its subsequent removal has been reported; an unfavorable outcome was observed in this case [4]. On the other hand, a mediastinitis following a SVC replacement for recurrent thyroid cancer was successfully treated by epiplooplasty and antibiotherapy [4]. Closed pleural drainage with irrigation would represent another therapeutic option.
In our case, we decided to maintain the graft, to eradicate the source of infection (completion pneumonectomy), and to cover both the graft, the bronchial stump, and the formerly infected area with a latissimus dorsi flap. In fact, graft removal almost always provokes an acute SVC syndrome, a life-threatening condition in a severely ill patient.
Muscle flaps have been reported to successfully prevent bronchial fistulas in high-risk patients previously treated by high-dose radiotherapy [6]. Transposition of muscles is a well-recognized technique to fill thoracostomy cavities, also in the presence of residual infection [7]. Furthermore, it has been recognized that myoplasty for infected vascular graft in the groin is safe and effective [8]. Even if the flap did not completely filled the right hemothorax, we did not perform systematic pleural irrigation and, finally, we removed the chest tube on day 5 without filling the space with antibiotic solution because no positive gram stains were identified in the postoperative course. In our opinion, a favorable outcome was possible because it was a localized empyema and all the previously infected area could be covered by the muscle flap.
Empyema still represents a life-threatening complication of lung resection with SVC replacement. Muscular transposition could represent a useful tool in the management of this condition.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. Spaggiari, P. Solli, G. Veronesi, and U. Pastorino Intrathoracic myoplasty for prosthesis infection after superior vena cava replacement for lung cancer Ann. Thorac. Surg., October 1, 2002; 74(4): 1231 - 1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Spaggiari, P. Thomas, P. Magdeleinat, H. Kondo, G. Rollet, J. F. Regnard, R. Tsuchiya, and U. Pastorino Superior vena cava resection with prosthetic replacement for non-small cell lung cancer: long-term results of a multicentric study Eur. J. Cardiothorac. Surg., June 1, 2002; 21(6): 1080 - 1086. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |